High-Throughput Screening (HTS) Market is Segmented By Technology (Ultra-high-throughput Screening, Cell-based Assays, Lab-on-a-chip, Label-free Technology, Others), By Application (Target Identification, Primary Screening, Toxicology, Other), the By End-User (Pharmaceutical and Biotechnology, Academia and Research Institutes, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
High-Throughput Screening (HTS) Market Overview
The High-Throughput Screening (HTS) Market report provides an analysis of the market shares, size, recent trends, future market outlook, and competitive intelligence. The demand for high-throughput screening (HTS) is increasing due to its potential to accelerate drug discovery, reduce costs and improve efficiency. The market is witnessing a surge in demand from the pharmaceutical and biotechnology industries. The competitive rivalry is intensifying with major players such as Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation and others actively operating in the market.
High throughput screening rapidly tests thousands to millions of samples for biological activity at the model organism, cellular, pathway, or molecular level using automated equipment (HTS).
High-throughput screening (HTS) Market scope
|
Metrics |
Details |
|
Market CAGR |
8% |
|
Segments Covered |
By Technology, By Application, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
High-Throughput Screening (HTS) Market Dynamics
The factors influencing the global high-throughput screening (HTS) market are the increasing advantages and the growing technological advancements that are expected to drive market growth.
The increasing advantages of high-throughput screening (HTS) are expected to drive market growth in the forecast period
HTS is required to test the compounds in functional or binding assays simultaneously. HTS is used in the drug discovery process to quickly screen the biochemical activity of many drug-like compounds. A plate, or tray, is at the heart of the HTS system, consisting of tiny wells into which assay reagents and samples are deposited and their reactions monitored. In a single day, HTS systems can evaluate tens of thousands, if not hundreds of thousands, of compounds. The amount of data for each experiment grows as the throughput grows, and scientists analyze and derive results from large amounts of data. Because of the large number of samples processed and the large amount of data generated, extensive automation techniques are required to streamline operations. One of the benefits of HTS is that it can be used even if the structure of a target protein is unknown.
Furthermore, HTS can be used to identify inducible pockets in protein-protein interfaces and allosteric modulators. The primary goal of the HTS technique is to accelerate drug discovery by screening large compound libraries at a rate of a few thousand compounds per day or week. Because parallel and combinatorial chemical synthesis generates many novel compounds. HTS's effectiveness in identifying target-specific compounds can be attributed to its laser-like focus on a single mechanism. The evolution of this technology is closely linked to changes in chemical synthesis strategy. Many scientists are interested in combinatorial chemistry because of the large number of compounds that can be produced and the ability to test many compounds in a short period. Various techniques such as fluorescence resonance energy transfer (FRET) and homogeneous time-resolved fluorescence (HTRF) are available for compound identification.
Limitations associated with high-throughput screening (HTS) are expected to hamper the market growth
Automation necessitates large investments in machinery and supporting infrastructure, which is prohibitive for small and medium-sized research institutes. As a result, the high costs associated with automation techniques may stifle market growth. Moreover, the low hit rate due to incompatible libraries and the potential for false positives are both drawbacks. One of the most successful examples of identifying PPI inhibitors through HTS is the discovery of Butlins and benzodiazepinediones as p53–MDM2 inhibitors. RG7112, a nutlin derivative, is currently in Phase I clinical trials for the treatment of leukaemia and solid tumors. Hence, the limitations are expected to hamper the market growth.
COVID-19 Impact on High-Throughput Screening (HTS) Market Growth
Several established pharmaceutical and biopharmaceutical companies have stepped forward to develop treatments following the World Health Organization's declaration of the COVID-19 outbreak as a pandemic. In just a few weeks, scientists discovered a list of molecules that target COVID-19. There are currently 79 vaccine candidates in development, 20 of which are in stage 3 clinical trials. In several countries, 11 vaccines have been approved to date. Four promising drugs have been repurposed against COVID-19 (Remdesivir, Chloroquine & Hydroxychloroquine, Lopinavir & Ritonavir, and Lopinavir with Ritonavir plus Interferon beta-1a). The WHO announced on March 24, 2020, that it had started a global mega trial of the four most promising COVID-19 drugs. Furthermore, researchers in several countries are examining the potential of various existing drugs to treat COVID-19. With high-throughput screening products being used for drug discovery, the market is expected to grow due to increased drug discovery projects for the development of COVID-19 treatments.
High-Throughput Screening (HTS) Market Segment Analysis
Based on end-user, the pharmaceutical and biotechnology segment is expected to dominate the market growth
Most large and small biotechnology and pharmaceutical companies are focusing on developing novel molecules to treat a variety of chronic conditions to gain a sustainable competitive advantage. Furthermore, new drug therapy approvals by the FDA's Center for Drug Evaluation and Research (CDER) aided a wide range of patients suffering from various medical conditions. The adoption of automated high-throughput screening techniques to screen massive chemical and biomarker libraries generated during the research processes has resulted from the need for rapid and precise screening of several target molecules during the drug discovery and development phases. Because an automated
HTS system can test 10,000 to 100,000 target compounds per day, and uHTS can test more than 100,000 compounds per day, their use in the drug discovery and development process is growing. Drug discovery aims to find new antitumoral drugs, which is a highly complex and multidisciplinary process. The current drug discovery protocols' screening attrition rate suggests that one marketable drug emerges from approximately one million screened compounds. As a result, there is a push to screen larger libraries to keep the pipeline going and develop High Throughput Screening. HTS refers to specific developments in laboratory automation that allow for the collection of large amounts of experimental data in a short amount of time. Hundreds of thousands of compounds can be tested per day using HTS. Hence, the use of HTS in the pharmaceutical and biotechnology industry is expected to drive market growth.
High-Throughput Screening (HTS) Market Geographical Share
North America region is expected to hold the largest market share in the global high-throughput screening (HTS) market
The factors driving the growth of the HTS market in this region include rising disease prevalence, rising pharmaceutical R&D expenditure, and the presence of major players. For instance, PerkinElmer, Inc. is a multinational corporation based in the United States. The company's Ultra-High Throughput Screening Platform with Multiple Modules is a one-of-a-kind, multimodule system that combines ultra-high-throughput screening and high content screening (HCS) into a single platform. Hence, the growing presence of key players in this region is expected to boost market growth.
High-Throughput Screening (HTS) Companies and Competitive Landscape
High-Throughput Screening (HTS) Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Agilent Technologies Inc., Axxam SpA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., Tecan Group Ltd, Hamilton Company, Aurora Biomed, Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Overview: Bio-Rad Laboratories, Inc. is based in the United States that develops and manufactures specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952.
Product Portfolio: The ZE5 Cell Analyzer is a high-performance flow cytometer that can be automated. It offers high-throughput screening and high-parameter cell analysis.
Key Development: On 30th June 2020, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc. to develop and commercialize infectious disease molecular diagnostic products, as well as to expand its presence in the high-throughput screening market.
